Despite a challenging consumer environment, the CEO remains confident due to the strength of the private brands market. However, the company's shares fell 6.36% in premarket trading post-earnings report.
TreeHouse Foods' steady decrease in revenue and share price over the past five years warns potential investors about possible future underperformance. Contrarian investors, however, might see a turnaround opportunity.
The company's CEO expressed optimism about capitalizing on the increasing consumer shift to private brands and believes actions taken to strengthen their portfolio and enhance capabilities, along with reinvestment opportunities, will ensure long-term value creation for shareholders.
The acquisition is expected to deepen TreeHouse Foods' position in the pickle category and facilitate expansion into Canada, potentially positioning the company for continued success.
RDK79 :
Only noted more downgraded than upgrades, lot of analysts late to the party. And a bunch of new ‘initiated’ by mostly unknown folks, but also a few surprised weren’t previously covered, like DIS.
ツリーハウス・フーズに関するコメント
コラムIndustries with opportunities for third-quarter financial reports!
$S&P 500 Index(.SPX.US)$$NASDAQ-100(2406)(NQmain.US)$$ウォルマート(WMT.US)$$スターバックス(SBUX.US)$$アマゾン・ドット・コム(AMZN.US)$$コストコホールセール(COST.US)$$イーライリリー(LLY.US)$$マクドナルド(MCD.US)$$ツリーハウス・フーズ(THS.US)$$ダーデン・レストランツ(DRI.US)$$カーマックス(KMX.US)$$ウェンディーズ(WEN.US)$
TOP WATCH 7/3 ⚡️⚡️
$エイピックス・メディカル(APYX.US)$$Addentax Group Corp(ATXG.US)$$アクサム・セラピューティクス(AXSM.US)$$バイオエクセル・セラピューティクス(BTAI.US)$$Baudax Bio(BXRX.US)$$CymaBay Therapeutics(CBAY.US)$$コーメディックス(CRMD.US)$$マリオット・インターナショナル(MAR.US)$$マイクロビジョン(MVIS.US)$$レナリティクスAI(RNLX.US)$$ステート・ストリート(STT.US)$$ツリーハウス・フーズ(THS.US)$$タルガリソース(TRGP.US)$$VBIウ゛ァクシンズ(VBIV.US)$$ベンタス(VTR.US)$
コラムToday's pre-market stock movers: PLTR, BBBY, BNTX, GOLD and more
In reaction to earnings/guidance:
• $Karuna Therapeutics(KRTX.US)$ +42.6% (also reports topline results from its Phase3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of its lead investigational therapy, KarXT), $マンデー・ドット・コム(MNDY.US)$ +15.1%,$W&Tオフショア(WTI.US)$ +6.7%,$HFシンクレア(DINO.US)$ +5.3%,$ヴィアトリス(VTRS.US)$ +4.3%,$コスモス・エナジー(KOS.US)$ + 3.2%,$Holly Energy(HEP.US)$ +3.2%,$バリック・ゴールド(GOLD.US)$ +2.9%,...
コラムToday's pre-market stock movers: BNTX, JPM, RIVN, HPQ and more
• $ジェンコ・シッピング&トレーディング(GNK.US)$ +4.7% (positive Barrons article)
• $ネクストデケード(NEXT.US)$ +4.7% (files for 4618226 share common stock offering by selling shareholder)
• $コンパス・パスウェイズ(CMPS.US)$ +4.7% (COMPASS Pathways presents largest ever study of psilocybin therapy at American Psychiatric Association annual meeting)
• $カヌー(GOEV.US)$ +3.5% (files for 48043111 share common stock offering by selling shareholder)
• $アメリカン・アクスル&マニュファクチャリング・ホールテ(AXL.US)$ +3.7% (pr...
コラムTop upgrades and downgrades on 5/23
• $キューブスマート(CUBE.US)$ : Raymond James Upgrades to Strong Buy from Outperform - PT $52 (from $60)
• $DTEエナジー(DTE.US)$ : Credit Suisse Upgrades to Outperform from Neutral - PT $140 (from $142)
• $コンソリデーテッド・エジソン(ED.US)$ : Guggenheim Upgrades to Neutral from Sell - PT $94 (from $80)
• $モトローラ ソリューションズ(MSI.US)$ : Morgan Stanley Upgrades to Overweight from Equalweight - PT $240
• $グルポ・エアロポルチュアリオ・デル・セントロ・ノルテ(OMAB.US)$ : Morgan Stanley Upgrades to...
shorts the only thing working for me today
まだコメントはありません